Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: Efficacy in joint and ocular disease [5]

Annals of the Rheumatic Diseases

Volumn 66, Issue 6, 2007, Pages 840-841

  Sharma, Srilakshmi M ^a,c   Ramanan, Athimalaipet V ^b   Riley, Philip ^b   Dick, Andrew D ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^c or 97239 4197   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR;

ABSENCE OF SIDE EFFECTS; ARTHRITIS; ARTHROPATHY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; EYE INFLAMMATION; EYE SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LOW DRUG DOSE; OSTEOPOROSIS; PRIORITY JOURNAL; REMISSION; RHEUMATIC DISEASE; TREATMENT FAILURE; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DRUG EVALUATION; HUMANS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 34249782273     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.065441     Document Type: Letter

References (8)

1. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006;65:1044-9.
2. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005;33:461-8.
3. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor {alpha} inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006;45:982-9.
4. Ravindran T, Rajaraman, Yukiko K, Li S, Haines K, Chu DS. Retrospective case review of paediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308-14.
5. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23.
6. Jabs DA, Gérard HC, Wei Y, Campbell AL, Hudson AP, Akpek EK, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
7. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7.
8. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12.